Repligen - RG-1068


Public list: Pharma Startups (4733) Cancer Therapeutics (1133)

Repligen (NASDAQ:RGEN) is a life sciences company focused on the development and commercialization of high-value consumable products used in the process of manufacturing biological drugs. The company's bioprocessing products are sold to major life sciences and biopharmaceutical companies worldwide. Repligen is a manufacturer of Protein A affinity ligands, a critical component of Protein A media that is used to separate and purify monoclonal antibody therapeutics.

Repligen (NASDAQ:RGEN) is a life sciences company focused on the development and commercialization of high-value consumable products used in the process of manufacturing biological drugs. The company's bioprocessing products are sold to major life sc...Show all

Company (Acquired)

Phone: 781-250-0111

Fax:

41 Seyon Street
Building #1, Suite 100
Waltham, 02453
Massachusetts, United States

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
Repligen - RG-1068 $0M Jan 6, 2015

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related Repligen - RG-1068 Jobs

jobs by Indeed job
						search
There is no Board of Directors data available for this company. Please select another tab.
There is no Competitors data available for this company. Please select another tab.

Patents

Title Application Date Patent Date Status
(Patent / Application)